SCHEMBL11903216

SCHEMBL11903216

CC(NC(=O)OC(C)(C)C)C(=O)Nc1ccccc1Nc1ccccc1.Nc1cccc(-c2ccccc2)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.41
HDAC3 O15379 3/20 0.41
HDAC4 P56524 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
AAK1 Q2M2I8 4/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
JAK2 O60674 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901156 0.86 CTSS (0.43) HDAC1HDAC4HDAC8JAK2ALDH1A1
SCHEMBL12682883 0.81 DDX3X (0.44) HDAC1HDAC3HDAC4HDAC2HDAC10
SCHEMBL9286086 0.79 AAK1 (0.51) HDAC1HDAC3HDAC2AAK1JAK2
SCHEMBL9283981 0.79 AAK1 (0.51) HDAC1HDAC3HDAC2AAK1JAK2
SCHEMBL6831599 0.78 ALDH1A1 (0.45) AAK1JAK2ALDH1A1CYP3A4CYP2D6
SCHEMBL11901700 0.77 EGFR (0.48) HDAC1HDAC3HDAC4HDAC2HDAC10
SCHEMBL11901699 0.76 CTSS (0.43) HDAC1HDAC3HDAC4HDAC2HDAC10
SCHEMBL11901329 0.76 TSHR (0.43) HDAC1HDAC3HDAC4HDAC2HDAC10
SCHEMBL11902051 0.76 TSHR (0.43) HDAC1HDAC3HDAC4HDAC2HDAC10
SCHEMBL11902012 0.75 CTSS (0.41) HDAC1HDAC3HDAC4HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 HDAC1 698/4885HDAC3 684/4885HDAC4 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.